Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Gerald Hsu

Lymphoma · UCSF

View

Dr. Chadi Nabhan

Lymphoma · Ryght AI / USC

View

Dr. Mark Roschewski

Lymphoma · MSK

View

Dr. Matthew Matasar

Lymphoma · Rutgers Cancer Institute

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    JFDr. Jonathan Friedberg
    Leading Voice

    Dr. Jonathan Friedberg

    Hematology & Oncology · Lymphoma
    University of Rochester Medicine
    jonathanf

    Research

    Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma

    2025

    Via Leukemia & Lymphoma

    Research

    SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular Lymphoma

    2025

    Via JCO Oncology Advances

    Research

    Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

    2025

    Via Journal of Clinical Oncology

    Research

    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial

    2025

    Via Haematologica

    Research

    Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

    2025

    Via Blood Cancer Journal

    Research

    Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study

    2025

    Via Leukemia & Lymphoma

    Research

    Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort Study

    2025

    Via Journal of Adolescent and Young Adult Oncology

    Research

    Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma

    2025

    Via Blood Advances

    Research

    Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

    2025

    Via Journal of Clinical Oncology

    Research

    PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

    2025

    Via Blood

    Research

    Bringing Trustworthy Artificial Intelligence to the Clinical Forefront at: A Guide for Studies Testing Artificial Intelligence Models

    2025

    Via Journal of Clinical Oncology

    Research

    Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort

    2025

    Via Hematological Oncology

    Research

    Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

    2025

    Via Blood Cancer Journal

    Research

    Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study

    2025

    Via Leukemia & Lymphoma

    Research

    Sun Sets on Rituximab/Gemcitabine/Oxaliplatin as Bispecific Antibodies Rise: The SUNMO Trial

    2025

    Via Journal of Clinical Oncology